Federal regulators have told the infant formula industry that the contamination behind two U.S. botulism outbreaks and a global toxin event did not originate in the factories that packaged the formula. It arrived in the ingredients those factories bought.
In a letter to manufacturers, packagers, distributors, importers, and retailers, the FDA said it expects companies to exercise "substantive oversight of their suppliers," including understanding where ingredients come from, how they are produced, and whether the risks they carry are actually controlled.
For parents, the practical meaning is uncomfortable but clarifying. In each of these events, the formula was sealed and looked normal. Nothing a caregiver could have seen, smelled, or done differently at the kitchen counter would have prevented it.
Contamination That Started Before the Can Was Sealed
The letter names three events, and the details explain why the agency escalated.
The first was the ByHeart outbreak, which FDA has described as the first confirmed U.S. botulism outbreak linked to infant formula in nearly 50 years. In total, 48 infants became ill across 17 states, all requiring hospitalization, with no deaths reported. CDC declared that outbreak over in late February. FDA inspections identified Clostridium botulinum in a powdered milk ingredient, and investigators found the organism in unopened cans, not only in an opened container.
The second involves Nara Organics, which recalled its Whole Milk Organic Infant Formula in June after a separate multistate infant botulism investigation. CDC and FDA are still working that one, and the agency has said it remains in the early stages. FDA has flagged a shared ingredient supplier between the two outbreaks as an open line of inquiry.
The third was international. From December 2025 through February 2026, nearly 150 suspected and confirmed cases of cereulide intoxication were reported across 10 countries, traced to contaminated arachidonic acid oil, an ingredient added to formula to approximate components of breast milk. Cereulide is a heat-stable toxin produced by Bacillus cereus, meaning normal preparation temperatures do not destroy it. In early May, the a2 Milk Company recalled batches of imported a2 Platinum powder from the U.S. market after cereulide was detected.
The Import Alert Behind the ARA Oil Case
The regulatory tool that ended the ARA oil exposure is one most consumers have never heard of, and it is worth understanding because it is the mechanism the FDA letter tells industry to monitor.
On May 12, all ARA oil products, including ARA oil powder, from CABIO Biotech in Wuhan, China, became subject to FDA Import Alert 99-51. That alert provides for detention of human food products that appear to have been "prepared, packed, or held under insanitary conditions" resulting in chemical contamination.
Infant formula has its own standing alert as well. Import Alert 40-05 covers infant formula that appears adulterated or misbranded, and FDA revised it as part of a broader push to tighten oversight following the 2022 shortage.
FDA modifies these alerts continuously. Recent months have brought changes affecting infant formula, seafood, dried peppers, cheese, and cantaloupe, among other categories. The additions rarely generate headlines because no product is being pulled from a shelf. They operate at the border instead.
Detention Without Physical Examination, Explained
The phrase attached to most import alerts is detention without physical examination, and it does specific work.
Ordinarily, imported food arrives, and FDA inspects a sample of shipments. When a firm or a country-and-product combination lands on an import alert, that arrangement inverts. Shipments can be detained at the border without FDA testing them first, and the burden shifts to the importer to demonstrate the product complies before it enters commerce.
The advantage is speed. The agency does not have to catch each individual bad lot to stop a pattern. The limitation is equally clear: the tool only works on products that have not already entered the country, and in the ARA oil case the contaminated ingredient had already been incorporated into finished formula sold across 10 countries before the alert was issued.
That sequence is the reason FDA wrote to industry rather than simply adding another alert. A border tool cannot substitute for a manufacturer verifying its own supplier.
Recall Checking Beats Visual Inspection
The single most useful behavior change for a caregiver here is unglamorous. Check recall lists rather than inspecting the can.
Powdered infant formula linked to these outbreaks caused illness from sealed, unopened containers. Appearance, smell, and texture told no one anything. FDA and CDC both maintain current recall and outbreak pages, and retailers post notices, but neither replaces checking the lot code on the container you actually have at home.
FDA advises keeping an opened container rather than discarding it if an infant becomes ill, labeling it clearly as not for use and storing it away from other feeding items, because a state health department may want to test it.
Parents should not switch formulas abruptly on the basis of a news report. Formula changes have their own consequences for feeding tolerance and nutrition, and the right move is a conversation with a pediatrician, particularly for infants on a specialty formula. FDA has said the Nara Organics recall involves less than one percent of U.S. infant formula sales and does not create shortage concerns.
Signs in an Infant That Need Same-Day Attention
Infant botulism is rare, and it does not look like a stomach bug, which is why it is missed.
It often begins with constipation, but the signs that typically prompt a parent to call are feeding difficulty (trouble sucking or swallowing), a weak or altered cry, drooping eyelids or reduced facial expression, and loss of head control or a generally floppy quality. It can progress to difficulty breathing.
Symptoms can take days to weeks to appear after formula ingestion, so a recall announced today may concern a feeding from a month ago.
Any infant showing these signs needs immediate medical evaluation. Infant botulism is treated with a specific immune globulin available through the California Department of Public Health's Infant Botulism Treatment and Prevention Program, and earlier treatment shortens hospitalization. Parents should not wait to see whether the symptoms improve overnight.
FDA has completed initial surveillance on the prevalence of Clostridium botulinum in powdered milk and continues to investigate root causes of both the 2025 and 2026 outbreaks. MedicalDaily will monitor the agency's post-outbreak response page and any expansion of the current recalls.
Frequently Asked Questions
Which formulas were recalled? ByHeart recalled its powdered infant formula products in November 2025, and Nara Organics recalled its Whole Milk Organic Infant Formula in June 2026. Separately, a2 Milk recalled certain batches of imported a2 Platinum powder in May 2026 over cereulide.
Can I tell if a can is contaminated? No. Illness occurred from sealed, unopened containers with no visible or detectable sign. Check lot codes against current recall notices instead of inspecting the product.
What is cereulide? A heat-stable toxin produced by Bacillus cereus. Because it withstands heat, normal formula preparation does not destroy it. It was traced to contaminated ARA oil used as a formula ingredient.
What does an import alert do? It allows FDA to detain shipments from a listed firm or product category at the border without testing each one first, shifting the burden to the importer to show compliance before entry.
What are the warning signs of infant botulism? Constipation, trouble sucking or swallowing, a weak or altered cry, drooping eyelids, reduced facial expression, and loss of head control. It can progress to breathing difficulty and needs immediate medical evaluation.
How long after feeding can symptoms appear? Days to several weeks. A recall announced now may relate to a feeding from weeks earlier.
Should I switch formulas? Not based on a news report alone. Talk with your pediatrician first, especially if your infant uses a specialty formula. FDA has said the current recall does not create supply shortage concerns.
